← Oncology Approval Tracker

FDA DECISION ·

Oziltus

denosumab-mobz · Amneal Pharmaceuticals

Biosimilar approvalBiosimilarCancer-related skeletal complications and giant cell tumor of bone
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Xgeva biosimilar for preventing skeletal complications in multiple myeloma or solid tumor bone metastases, treating giant cell tumor of bone in eligible adults and skeletally mature adolescents, and treating malignancy-related hypercalcemia refractory to bisphosphonates.

LAMPGEN ANALYSIS

Why it matters

This oncology-dose denosumab approval adds a biosimilar option for the labeled Xgeva uses.

What research teams should watch

Keep the oncology-dose product and endocrine bone loss product separate in inventory and preadministration checks.

PRIMARY RECORDS

Sources